Aurinia Pharmaceuticals (AUPH) Projected to Release Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will likely be releasing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $0.21 per share and revenue of $80.9370 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.07. Aurinia Pharmaceuticals had a return on equity of 26.62% and a net margin of 99.97%.The company had revenue of $77.71 million for the quarter, compared to the consensus estimate of $76.98 million. On average, analysts expect Aurinia Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Aurinia Pharmaceuticals Stock Down 2.0%

Shares of Aurinia Pharmaceuticals stock opened at $15.33 on Thursday. Aurinia Pharmaceuticals has a one year low of $8.80 and a one year high of $19.25. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.55 and a quick ratio of 5.01. The stock’s 50-day moving average is $16.01 and its 200 day moving average is $15.36. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of 7.06 and a beta of 1.41.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Zacks Research upgraded Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Weiss Ratings cut Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Aurinia Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $17.25.

Insider Buying and Selling

In other Aurinia Pharmaceuticals news, CEO Kevin Tang acquired 206,005 shares of the stock in a transaction on Tuesday, June 2nd. The shares were purchased at an average price of $15.28 per share, for a total transaction of $3,147,756.40. Following the completion of the acquisition, the chief executive officer owned 13,044,106 shares in the company, valued at approximately $199,313,939.68. This represents a 1.60% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have acquired 814,606 shares of company stock worth $12,455,129. Insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AUPH. Arrowstreet Capital Limited Partnership increased its position in shares of Aurinia Pharmaceuticals by 213.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,374,021 shares of the biotechnology company’s stock worth $37,283,000 after acquiring an additional 2,297,903 shares in the last quarter. Marshall Wace LLP lifted its position in Aurinia Pharmaceuticals by 1,272.5% in the 3rd quarter. Marshall Wace LLP now owns 1,483,132 shares of the biotechnology company’s stock valued at $16,389,000 after acquiring an additional 1,375,072 shares in the last quarter. Kotler Kevin bought a new position in Aurinia Pharmaceuticals in the 4th quarter valued at about $19,536,000. Two Sigma Investments LP boosted its stake in Aurinia Pharmaceuticals by 728.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company’s stock valued at $14,819,000 after purchasing an additional 1,179,219 shares during the last quarter. Finally, Man Group plc boosted its stake in Aurinia Pharmaceuticals by 368.9% during the 4th quarter. Man Group plc now owns 852,671 shares of the biotechnology company’s stock valued at $13,600,000 after purchasing an additional 670,812 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.